Jpmorgan Chase & CO Inmune Bio, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 5,202 shares of INMB stock, worth $31,420. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,202

Holding current value

$31,420

% of portfolio

0.0%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 12, 2024	BUY	$7.15 - $11.84 $37,194 - $61,591	5,202 New	5,202 $45,000
Q4 2023 Feb 12, 2024	BUY	$6.6 - $11.52 $22,961 - $40,078	3,479 New	3,479 $39,000

Others Institutions Holding INMB

# of Institutions

Shares Held

4.78M

Call Options Held

80K

Put Options Held

41.8K

Black Rock Inc. New York, NY

813K
Shares

$4.91 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

628K
Shares

$3.79 Million
0.0% of portfolio
Cvi Holdings, LLC Wilmington, DE

596K
Shares

$3.6 Million
45.87% of portfolio
Praetorian Pr LLC Rincon, PR

485K
Shares

$2.93 Million
1.57% of portfolio
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL

369K
Shares

$2.23 Million
0.0% of portfolio

View Full List

About Inmune Bio, Inc.

Ticker INMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,946,000
Market Cap $108M
Description
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...

More about INMB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account